Lin Gen, Fan Xirong, Zhu Weifeng, Huang Cheng, Zhuang Wu, Xu Haipeng, Lin Xiandong, Hu Dan, Huang Yunjian, Jiang Kan, Miao Qian, Li Chao
Department of Thoracic Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou 350014, China.
Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou 350014, China.
Oncotarget. 2017 Aug 12;8(48):83986-83994. doi: 10.18632/oncotarget.20233. eCollection 2017 Oct 13.
Programmed death ligand 1 (PD-L1) expression is a predictive biomarker of the success of PD-1/PD-L1 inhibitor therapy for patients with advanced non-small cell lung cancer (NSCLC) but its role as a prognostic marker for early stage resectable NSCLC remains unclear. Here, we studied PD-L1 expression and tumor infiltrating lymphocytes (TILs) in surgically resectable NSCLC and correlate the finding with clinicopathological features and patient outcomes. Total of 170 archival samples of resectable NSCLC were probed for PD-L1 expression using the clone 22C3 pharmDx kit. The PD-L1 expression was determined by the Tumor Proportion Score (TPS) and classified into TPS <1%, TPS 1 to 49% and TPS ≥50%. The scoring of TILs was from hematoxylin & eosin stained tissue sections using a system for standardized evaluation of TILs in breast cancer. PD-L1 expression was compared with clinical pathological characteristics and survival outcome. Expression of PD-L1 scores of TPS ≥50%, TPS 1 to 49% and TPS <1% were observed in 10.6%, 24.7% and 64.7% of the 170 archival samples, respectively. Positive PD-L1 expression was significantly higher in patients with squamous carcinoma, in those with higher TNM stage and with the presence of TILs. Neither the PD-L1 expression, TIL status, nor their combination was an independent prognosis biomarker of survival when the data was subjected to either univariate or multivariate analysis. The incidence of PDL1 expression appears to be lower in patient with early stage resectable lung cancer. PD-L1 expression and TILs are not prognostic indicators of survival outcome in this population.
程序性死亡配体1（PD-L1）表达是晚期非小细胞肺癌（NSCLC）患者接受PD-1/PD-L1抑制剂治疗成功的预测生物标志物，但其作为早期可切除NSCLC预后标志物的作用仍不清楚。在此，我们研究了手术可切除NSCLC中PD-L1表达和肿瘤浸润淋巴细胞（TILs），并将结果与临床病理特征和患者预后相关联。使用克隆22C3药物诊断试剂盒对170份可切除NSCLC存档样本进行PD-L1表达检测。通过肿瘤比例评分（TPS）确定PD-L1表达，并分为TPS<1%、TPS 1至49%和TPS≥50%。使用乳腺癌TILs标准化评估系统，通过苏木精和伊红染色的组织切片对TILs进行评分。将PD-L1表达与临床病理特征及生存结果进行比较。在170份存档样本中，TPS≥50%、TPS 1至49%和TPS<1%的PD-L1表达率分别为10.6%、24.7%和64.7%。鳞状细胞癌患者、TNM分期较高患者及存在TILs的患者中，PD-L1阳性表达显著更高。当对数据进行单因素或多因素分析时，PD-L1表达、TIL状态及其组合均不是生存的独立预后生物标志物。早期可切除肺癌患者中PDL1表达的发生率似乎较低。在该人群中，PD-L1表达和TILs不是生存结果的预后指标。
